| . | Placebo, n (%) . | Atomoxetine, n (%) . | Total . |
|---|---|---|---|
| Asymptomatic | 6 (22) | 6 (21) | 12 |
| Isolated presyncope | 2 (7) | 13 (45) | 15 |
| Syncope | 19 (70) | 10 (34) | 29 |
| Total | 27 (100) | 29 (100) | 56 |
| . | Placebo, n (%) . | Atomoxetine, n (%) . | Total . |
|---|---|---|---|
| Asymptomatic | 6 (22) | 6 (21) | 12 |
| Isolated presyncope | 2 (7) | 13 (45) | 15 |
| Syncope | 19 (70) | 10 (34) | 29 |
| Total | 27 (100) | 29 (100) | 56 |
P = 0.003 by Fisher’s exact with Halton–Freeman extension. Of 15 subjects with presyncope as an outcome 87% had received atomoxetine. The relative risk reduction for syncope was 0.49 (confidence interval 0.28–0.86, P = 0.012). Percentages in the individual subgroups within the placebo arm do not add up to 100% due to rounding.
| . | Placebo, n (%) . | Atomoxetine, n (%) . | Total . |
|---|---|---|---|
| Asymptomatic | 6 (22) | 6 (21) | 12 |
| Isolated presyncope | 2 (7) | 13 (45) | 15 |
| Syncope | 19 (70) | 10 (34) | 29 |
| Total | 27 (100) | 29 (100) | 56 |
| . | Placebo, n (%) . | Atomoxetine, n (%) . | Total . |
|---|---|---|---|
| Asymptomatic | 6 (22) | 6 (21) | 12 |
| Isolated presyncope | 2 (7) | 13 (45) | 15 |
| Syncope | 19 (70) | 10 (34) | 29 |
| Total | 27 (100) | 29 (100) | 56 |
P = 0.003 by Fisher’s exact with Halton–Freeman extension. Of 15 subjects with presyncope as an outcome 87% had received atomoxetine. The relative risk reduction for syncope was 0.49 (confidence interval 0.28–0.86, P = 0.012). Percentages in the individual subgroups within the placebo arm do not add up to 100% due to rounding.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
